C.S. Denlinger
YOU?
Author Swipe
View article: A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors
A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors Open
Background: MEDI1873 is a novel GITR-ligand/IgG1 agonist fusion protein that binds the co-stimulatory glucocorticoid-induced TNF receptor family-related protein (GITR) on CD4+ and CD8+ effector T cells and regulatory T cells. This Phase 1 …